S. Ashida

Factors Associated With Prolonged Psychological Distress Among Nurses and Physicians Engaged in COVID-19 Patient Care in Singapore and Japan

S. Kutsuna, N. Ohmagari, Y. Asai, 2022, Frontiers in Psychiatry.

Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants

T. Okamura, N. Nagata, Tadaki Suzuki, 2022, Antiviral Research.

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)

M. Satake, Y. Takamatsu, S. Kutsuna, 2022, Life.

Epidemiology of post-COVID conditions beyond 1 year: a cross-sectional study

S. Kutsuna, N. Ohmagari, S. Tsuzuki, 2023, Public Health.

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial

Akiko Kimura, M. Satake, Y. Takamatsu, 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Interferon lambda 3 in the early phase of coronavirus disease‐19 can predict oxygen requirement

M. Sugiyama, M. Mizokami, N. Ohmagari, 2022, European journal of clinical investigation.

Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox

M. Shimojima, H. Ebihara, N. Ohmagari, 2023, BMJ open.

Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan.

W. Sugiura, N. Ohmagari, N. Kokudo, 2021, Global health & medicine.

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial

S. Kutsuna, N. Ohmagari, I. Hamaguchi, 2023 .